App-Quantinova.ai

Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.

Pedro Nazareth Aguiar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC).

Rathi Narayana Pillai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

Measurement of spatial and antibody-based PD-L1 heterogeneity in non-small cell lung cancer.

Patricia Gaule - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067).

Jedd D. Wolchok - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Ipilimumab

Efficacy and safety of PD-1 blockade in metastatic uveal melanoma

Katy K. Tsai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Uveal melanoma

Pembrolizumab

KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy.

Adil Daud - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

Responses in patients with BRAF V600-mutant metastatic melanoma receiving anti-PD1/PDL1 therapy alone or combined with BRAF inhibitors.

Edelyn Barcena - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Development of a clinical trial assay for PD-L1 immunohistochemistry (IHC) for use with pembrolizumab (pembro) clinical trials in melanoma.

Marisa Dolled-Filhart - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Pembrolizumab

PD-L1, B7-H3, and PD-1 expression in immunocompetent versus immunosuppressed patients with advanced cutaneous squamous carcinoma (cSCC).

Vinod Varki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cutaneous squamous cell carcinoma

N/A

Patterns of PD-1, PD-L1 and PD-L2 expression in pediatric solid tumors.

Navin R. Pinto - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity.

Maud Toulmonde - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Sarcoma

N/A

Association of PD-L2 expression in human tumors with atezolizumab activity.

Peter Schmid - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Atezolizumab

Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues.

Robbie G. Majzner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Distribution of PD-L1 expression in diverse cancer types: Experience with over 10,000 cases.

Zoran Gatalica - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

SP263

PD-L1 expression correlation with TP53 gene mutation status in lung cancer but not in colorectal cancer.

Sally Agersborg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

TP53

Quantitative image analysis of PD-L1, CD8, CD3, CD68 and FoxP3 protein expression in lung and bladder cancer specimens by fully automated multiplex fluorescence immunohistochemistry.

Wenjun Zhang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer (LC): implications for immunotherapy.

David James Pinato - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Meta-analysis of tumor PD-L1 expression as a predictive biomarker of benefit from PD-1/PD-L1 axis inhibitors in solid tumors.

Monica Khunger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

PD-1, PD-L1, and B7-H3 expression in Human Immunodeficiency Virus (HIV) infected patients with aerodigestive (AD) cancers (CA).

Katherine Ann Scilla - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Companion and complementary diagnostics for PD-L1 expression assessment in non-small cell lung cancer.

Steven M. Anderson - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Filters

4177 Abstracts